Connor, Clark & Lunn Investment Management (CC&L)

Connor, Clark & Lunn Investment Management (CC&L)’s Oric Pharmaceuticals ORIC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.61M	Buy	522,061 +171,177	+49%	+$1.94M	0.02%	601
2025 Q4	$2.87M	Buy	350,884 +334,447	+2,035%	+$3.85M	0.01%	827
2025 Q3	$197K	Buy	+16,437	New	+$173K	﹤0.01%	1426
2024 Q4	–	Sell	-12,832	Closed	-$132K	–	1572
2024 Q3	$132K	Buy	+12,832	New	+$127K	﹤0.01%	1356
2023 Q2	–	Sell	-43,225	Closed	-$246K	–	1441
2023 Q1	$246K	Buy	43,225 +1,590	+4%	+$8.31K	﹤0.01%	1049
2022 Q4	$245K	Sell	41,635 -9,174	-18%	-$31K	﹤0.01%	1013
2022 Q3	$163K	Buy	50,809 +29,746	+141%	+$119K	﹤0.01%	1008
2022 Q2	$94K	Buy	+21,063	New	+$84K	﹤0.01%	983

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.34B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Viking Global Investors

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Alkeon Capital Management

Alkeon Capital Management New York $22.1B AUM 51.63% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return